adaptive(US) | $7,000,000 | (Apr 23, 2025)
Tally(US) | $8,000,000 | (Apr 23, 2025)
Recce | $4,000,000 | (Apr 23, 2025)
CND Life Sciences
United States
- Scottsdale, Arizona
- 07/04/2023
- Seed
- $4,500,000
CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified laboratory in Scottsdale, AZ, CND launched the Syn-One Test® as the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid in the confirmation of a synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through analysis of three small in-office skin biopsies provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field.
- Industry Medical and Diagnostic Laboratories
- Website https://cndlifesciences.com/
- LinkedIn https://www.linkedin.com/company/cnd-life-sciences/
UbiQD, Inc. | $20,000,000 | (Apr 23, 2025)
Arch Network | $13,000,000 | (Apr 23, 2025)
GreenFi | $17,000,000 | (Apr 23, 2025)
Hopper Security | $7,600,000 | (Apr 23, 2025)
Capably | $4,000,000 | (Apr 23, 2025)
Puresport | $4,788,090 | (Apr 23, 2025)
Reusables.com | $2,600,000 | (Apr 23, 2025)
Spur | $4,500,000 | (Apr 22, 2025)
Capsule | $12,000,000 | (Apr 22, 2025)